917389-32-3

Basic information

• Product Name: LeterMovir
• Synonyms: AIC246;LeterMovir;(4S)-8-Fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic acid;4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-, (4S)-;Letermovir (AIC246)
• CAS NO: 917389-32-3
• Molecular Formula: C₂₉H₂₈F₄N₄O₄
• Molecular Weight: 572.5506328
• Mol File: 917389-32-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 706.5±70.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility: ≥57.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
• PKA: 4.00±0.10(Predicted)
• CAS DataBase Reference: LeterMovir(CAS DataBase Reference)
• NIST Chemistry Reference: LeterMovir(917389-32-3)
• EPA Substance Registry System: LeterMovir(917389-32-3)

Safety Data

• Hazardous Substances Data: 917389-32-3(Hazardous Substances Data)

Usage

Description

Letermovir is an antiviral medication that acts as a cytomegalovirus terminus complex inhibitor. It is administered orally or intravenously and is used in the treatment of CMV infection, which is prevalent in individuals with immunocompromised systems.

Uses

Used in Antiviral Applications:
Letermovir is used as an antiviral agent for the treatment of CMV infection in immunocompromised individuals. It inhibits the activity of the cytomegalovirus terminus complex, thereby preventing the replication and spread of the virus.
Used in Immunocompromised Patient Care:
Letermovir is used in the healthcare industry as a treatment option for immunocompromised patients who are at a higher risk of developing CMV infection. By inhibiting the virus, Letermovir helps in managing and controlling the infection, reducing the severity of the symptoms and improving the overall health of the patients.

Upstream product

• 917389-30-1 (2S,3S)-2,3-bis[(4-methylbenzoyl)oxy]succinic acid {(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-(trifluormethyl)phenyl)-3,4-dihydroquinazolin-4-yl}acetic acid methyl ester 
• 917389-34-5 (R)-methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetate 
• 917389-21-0 methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-4-yl)acetate 
• 348-54-9 2-Fluoroaniline 
• 16588-75-3 2-methoxy-5-trifluoromethylphenyl isocyanate 
• 917389-24-3 N-(2-fluorophenyl)-N'-[2-methoxy-5-(trifluoromethyl)phenyl]urea 
• 65896-11-9 2-bromo-6-fluoroaniline 
• 791117-40-3 methyl 2-[8-fluoro-3-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl] acetate 
• 349-65-5 2-Methoxy-5-trifluoromethyl-aniline 
• 917389-23-2 3-(2-bromo-6-fluorophenyl)-1-[2-methoxy-5-(trifluoromethyl)phenyl]urea 
• 690664-20-1 methyl (2E)-3-(2-amino-3-fluorophenyl)acrylate 
• 6968-76-9 1-(3-methoxyphenyl)piperazine dihydrochloride 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF AN INTERMEDIATE USED IN THE SYNTHESIS OF LETERMOVIR

Disclosed is an enantioselective process for the preparation of letermovir of formula (I) which comprises enantioselective addition of (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)ethanone (IV), catalysed by TiCl4 on the imine of formula III, to give intermediate V, which is hydrolysed to the acid of formula VI and subsequently cyclised in the presence of organic bases to give intermediate VII, from which letermovir is obtained with good yields and a high degree of enantioselection.

NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS

Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.

DIHYDROQUINAZOLINE INHIBITORS OF VIRAL TERMINASE

The present invention relates to new dihydroquinazoline modulators of viral infection, pharmaceutical compositions thereof, and methods of use thereof.